Fig. 3

Performance of the 106-CDS panel for predicting the efficacy of immunotherapy in the test datasets. a Kaplan–Meier curves of progression-free survival (PFS) for the 59 advanced lung adenocarcinoma (LUAD) patients in the Matthew dataset. The p value was determined using log-rank test. The hazard ratio (HR) and 95% confidence interval (CI) were determined using univariate Cox regression models. b Multivariate Cox analysis for the 106-CDS panel, age, sex, and smoking status in the Matthew dataset. Solid circles represent the HR for mortality risk and the open-ended horizontal lines represent the 95% CI. The p value, HR, and CI were determined using multivariate Cox regression models. c Kaplan–Meier curves of PFS for the 29 advanced LUAD patients in the Rizvi dataset. The p value was determined using log-rank test. The HR and 95% CI were determined using univariate Cox regression models. d Multivariate Cox analysis of the 106-CDS panel, age, sex, and smoking status in the Rizvi dataset. The p value, HR, and CI were determined using multivariate Cox regression models